目的 探討瑞巴派特聯(lián)合鋁鎂加混懸液治療應(yīng)激性胃潰瘍的臨床療效。方法 選取2022年3月—2023年3月欽州市第二人民醫(yī)院收治的96例重癥應(yīng)激性胃潰瘍患者，按照隨機數(shù)字表法將所有患者分為對照組和治療組，每組各48例。對照組餐后1 h口服鋁鎂加混懸液，1袋/次，3次/d。治療組在對照組的基礎(chǔ)上口服瑞巴派特片，1片/次，3次/d。兩組連續(xù)用藥7 d。觀察和比較兩組的臨床療效和臨床癥狀緩解時間，比較兩組治療前后胃腸功能指標（胃動素、胃泌素、胃液pH值）、血管內(nèi)皮素-1（ET-1）、白細胞介素-6（IL-6）、血清降鈣素（PCT）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，治療組總有效率是97.92%，顯著高于對照組的81.25%（P＜0.05）。治療后，治療組腹痛、腹脹、燒灼痛、反酸等癥狀緩解時間均顯著短于對照組（P＜0.05）。治療后，兩組胃動素、胃液pH值較治療前顯著升高，而胃泌素顯著降低（P＜0.05）；治療后，治療組胃腸功能指標改善優(yōu)于對照組（P＜0.05）。治療后，兩組患者ET-1、IL-6、TNF-α、PCT水平均較同組治療前顯著降低（P＜0.05）；治療后，治療組ET-1、IL-6、TNF-α、PCT水平低于對照組（P＜0.05）。結(jié)論 瑞巴派特聯(lián)合鋁鎂加治療應(yīng)激性潰瘍效果確切，可修復(fù)損傷黏膜，有效增強胃腸功能，可抑制炎癥反應(yīng)及調(diào)節(jié)炎性因子釋放，值得臨床借鑒。

Objective To observe the clinical efficacy of rebamipide combined with almagate in treatment of stress gastric ulcer. Methods Ninety-six patients with severe stress gastric ulcer admitted to the Second People’s Hospital of Qinzhou from March 2022 to March 2023 were selected and divided into control group and treatment group according to random number table method, with 48 patients in each group. Patients in the control group were po administered with Almagate Suspension 1 h after meal, 1 bag/time, three times daily. Patients in the treatment group were po administered with Rebamipide Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 7 d. The clinical efficacy and symptom remission time of the two groups were observed and compared, and the levels of gastrointestinal function indexes (motilin, gastrin, pH of gastric juice), endothelin-1 (ET-1), interleukin-6 (IL-6), serum calcitonin (PCT) and tumor necrosis factor-α (TNF-α) before and after treatment were compared between two groups. Result After treatment, the total effective rate of the treatment group was 97.92%, which was significantly higher than that of the control group (81.25%, P < 0.05). After treatment, the remission time of abdominal pain, abdominal distension, burning pain and acid reflux in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the pH values of motilin and gastric juice in two groups were significantly increased, but gastrin were significantly decreased (P < 0.05). After treatment, gastrointestinal function indexes in the treatment group were better than those in the control group (P < 0.05). After treatment, the levels of ET-1, IL-6, TNF-α and PCT in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the levels of ET-1, IL-6, TNF-α and PCT in the treatment group were lower than those in control group (P < 0.05). Conclusion Rebamipide combined with almagate has a definite effect in treatment of stress gastric ulcer, and can repair damaged mucosa, effectively enhance gastrointestinal function, and also can inhibit inflammatory response and regulate the release of inflammatory factors, which is worthy of clinical reference.

R975

欽州市科學(xué)研究與技術(shù)開發(fā)計劃項目（20199504）